NEW YORK (GenomeWeb News) – Private equity firm GTCR today announced a partnership with former Gen-Probe executives Carl Hull and Eric Tardif to form Maravai Life Sciences.

Based in San Diego, Maravai will acquire diagnostics and life science companies and products "as part of a strategy to build a market-leading healthcare business," GTCR said, adding it is investing up to $300 million into the partnership.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.